Analysis for PSA

$295.33 +6.57 (+2.28%)

📈 Growth — 14/30
💰 Profitability — 18/20
🏦 Financial Health — 15/20
💵 Valuation — 12/20
⚠️ Risk — 6/10

Overall Score: 63/100

Summary:

📈 Growth & Financial Trajectory

Over the 7 reported quarters from 2024-Q2 to 2026-Q2, revenues rose from about $1.173B to about $1.233B, a modest gain of roughly 5%. Net income fluctuated, peaking in 2024-Q4 at $618M and dipping in 2025-Q1 to about $361M, before landing near $503M in 2026-Q2. Net operating cash flow remained robust, with quarterly figures such as $868.4M in 2026-Q2 and $872.7M in 2025-Q4, underscoring solid liquidity.

💰 Margins & Cash Flow

Operating margins trended around 39-41% across periods, with operating income reporting in the mid-$470-490M range on roughly $1.2B in revenues. Cash flow from operating activities stayed positive and sizable, evidence of recurring cash generation (e.g., $868.4M in 2026-Q2; $872.7M in 2025-Q4). Investing cash flow was modestly negative, while financing activity fluctuated, indicating standard REIT capital management.

🛡️ Balance Sheet & Liquidity

Total assets hovered near $20.0B, with equity near $9.6-9.9B and long-term debt around $9.4-10.6B. The mix supports strong liquidity and resilience against near-term stress; current liabilities align with asset levels, indicating a stable balance sheet profile.